An update on the medical therapy of advanced metastatic renal cell carcinoma

作者：Kruck Stephan; Merseburger Axel S; Gakis Georgios; Kramer Mario W; Stenzl Arnulf; Kuczyk Markus A^*

来源：Scandinavian Journal of Urology and Nephrology, 2008, 42(6): 501-506.

DOI：10.1080/00365590802203983

• Renal cell cancer
• tyrosine kinase
• metastatic
• medical therapy

The effectiveness of multikinase inhibitors in first- and second-line therapy of metastatic renal cell carcinoma (RCC) has been evaluated in various clinical studies. Initial results indicate an increased response rate and a prolonged progression-free survival compared with cytokine-containing therapeutic approaches. The new multitargeted kinase inhibitors sorafenib (Nexavar/BAY 43-9006) and sunitinib (Sutent/SUO 11248) interfere mainly with vascular endothelial growth factor and platelet-derived growth factor pathways. Recently, temsirolimus, a specific inhibitor of mammalian target of rapamycin, demonstrated activity in RCC patients with poor prognosis. This review discusses the effectiveness of the most frequently used substances for systemically progressive RCC in consideration of the currently available clinical data.

• 出版日期2008